Search

Your search keyword '"Talieri, Maroulio"' showing total 180 results
Start Over Author "Talieri, Maroulio"
180 results on '"Talieri, Maroulio"'

21. A comprehensive nomenclature for serine proteases with homology to tissue kallikreins

Author

Lundwall, Åke, Band, Vimla, Blaber, Michael, Clements, Judith A., Courty, Yves, Diamandis, Eleftherios P., Fritz, Hans, Lilja, Hans, Malm, Johan, Maltais, Lois J., Olsson, A. Yvonne, Petraki, Constantina, Scorilas, Andreas, Sotiropoulou, Georgia, Stenman, Ulf-Håkan, Stephan, Carsten, Talieri, Maroulio, and Yousef, George M.

Published
2006

29. Manfred Schmitt (1947–2018)

Author

Reuning, Ute, primary, Magdolen, Viktor, additional, Courty, Yves, additional, Clements, Judith A., additional, Yousef, George M., additional, Scorilas, Andreas, additional, Talieri, Maroulio, additional, and Diamandis, Eleftherios P., additional

Published
2018
Full Text
View/download PDF

32. Human kallikrein-related peptidase 12 (KLK12) splice variants expression in breast cancer and their clinical impact

Author

Talieri, Maroulio Devetzi, Marina Scorilas, Andreas Pappa, Eleana Tsapralis, Nikolaos Missitzis, Ioannis Ardavanis, Alexandros

Abstract

Kallikrein-related peptidases (KLKs) are a group of 15 serine proteases, hormonally regulated, and localized on chromosome 19q13.4. Alternative splicing is a process that plays significant role in the development, physiology, and different diseases, like cancer. Kallikrein family numbers more than 82 alternative transcripts. Understanding the role that those gene transcripts play in various cancer types, could lead to the discovery of diagnostic markers or drug targets. The present study was designed to analyze the expression profile of the splice variants of kallikrein-related peptidase 12 (KLK12) in breast cancer patients and to evaluate their clinical significance. KLK12 splice variants (KLK12sv3 and KLK12sv1/KLK12sv2) were examined in 69 tissue samples of breast cancer using quantitative real-time PCR as well as semi-quantitative PCR. Relative quantitative expression of KLK12 was statistically associated to clinicopathological parameters. From the splice variants examined, statistical associations with clinicopathological parameters were obtained only from KLK12sv3 variant. KLK12sv3 is more frequently expressed in tumors of lower grade (p = 0.040), early patient TNM stage (p = 0.024), and smaller tumor size (p = 0.023). Positive KLK12sv3 expression is associated with longer patient disease-free survival (DFS) (p = 0.042) and higher progesterone receptor concentration (p = 0.008). KLK12sv1/KLK12sv2 expression is statistically associated with KLK12sv3 expression (p = 0.001). KLK12sv3 can be regarded as a marker of good prognosis in breast cancer.

Published
2012

34. Sa1944 Immunohistochemical Localisation of Kallikrein-Related Protease 14 (KLK14) in Colon Tissues During Cancer Development: Expression and Clinical Evaluation

Author

Talieri, Maroulio, primary, Kypraios, Dimitrios, additional, Devetzi, Marina, additional, Papachristopoulou, Georgia, additional, Malachias, Apostolos, additional, Bassioukas, Stefanos P., additional, Stavrinides, Stavros, additional, Xinopoulos, Dimitrios, additional, and Theodoropoulos, Loukas, additional

Published
2015
Full Text
View/download PDF

36. Sa2001 Analysis of the Expression and Clinical Significance of Kallikrein-Related Peptidases 8 and 14 (Klk8 & Klk14) in Colon Cancer

Author

Kypraios, Dimitrios, primary, Brown, Marshall D., additional, Zheng, Yingye, additional, Devetzi, Marina, additional, Bassioukas, Stefanos P, additional, Katerinis, Panagiotis, additional, Malachias, Apostolos, additional, Xinopoulos, Dimitrios, additional, Arnogiannaki, Niki, additional, and Talieri, Maroulio, additional

Published
2013
Full Text
View/download PDF

41. Expression and Clinical Evaluation of Klk10 Gene in Colon Cancer

Author

Talieri, Maroulio, primary, Xinopoulos, Dimitrios, additional, Scorilas, Andreas, additional, Arnogiannaki, Niki, additional, Bassioukas, Stefanos P., additional, Kypreos, Dimitrios, additional, Poulakis, Apostolos, additional, Dimitroulopoulos, Dimitrios, additional, Loukou, Argyro, additional, and Paraskevas, Emmanouil, additional

Published
2011
Full Text
View/download PDF

44. Quantitative Reverse Transcription-PCR Assay for Detection of mRNA Encoding Full-Length Human Tissue Kallikrein 7: Prognostic Relevance of KLK7 mRNA Expression in Breast Cancer 3

Author

Holzscheiter, Leon, primary, Biermann, Julia C, primary, Kotzsch, Matthias, primary, Prezas, Panagiotis, primary, Farthmann, Juliane, primary, Baretton, Gustavo, primary, Luther, Thomas, primary, Tjan-Heijnen, Vivianne CG, primary, Talieri, Maroulio, primary, Schmitt, Manfred, primary, Sweep, Fred CGJ, primary, Span, Paul N, primary, and Magdolen, Viktor, primary

Published
2006
Full Text
View/download PDF

50. Cisplatin-Induced Apoptosis in HL-60 Human Promyelocytic Leukemia Cells.

Author

FLOROS, KOSTAS V., THOMADAKI, HELLINIDA, LALLAS, GEORGE, KATSAROS, NIKOS, TALIERI, MAROULIO, and SCORILAS, ANDREAS

Subjects
CISPLATIN, APOPTOSIS, LEUKEMIA, CELL culture, DNA, ALKYLATING agents, CELLS, CHLORIDES, ANTINEOPLASTIC agents
Abstract

The anti-apoptotic molecule BCL2 delays cell-cycle entry from quiescence. We have recently cloned a new member of the BCL2 family of apoptosis-related genes, BCL2L12. In the present study, the expression of BCL2 and BCL2L12 genes during cisplatin-induced apoptosis in HL-60 leukemic cells was investigated. The kinetics of apoptosis induction and cell toxicity were evaluated by DNA laddering and the MTT method, respectively. BCL2 and BCL2L12 expression was analyzed by RT-PCR using gene-specific primers. The ratio of apoptotic cells increased with increasing concentrations of cisplatin and exposure time of cell culture to the drug. Gradual, time-dependent downregulation of BCL2 gene was observed during cisplatin treatment. Up-regulation of BCL2L12 was observed 3 h (no DNA fragmentation) and 6 h (initiation of the DNA fragmentation) after treatment with cisplatin, followed by a decrease of its expression after 12-h continuous treatment with the drug. It is known that the main anti-carcinogenic effect of cisplatin is due to the induction of cell apoptosis. Present results indicate that downregulation of the BCL2 and upregulation of the BCL2L12 gene may be the underlying mechanisms. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results